• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Right Arrow Button IconLeft Arrow Button IconHome
Right Arrow Button IconEli Lilly

Eli Lilly

Page 4 of 7
WHO
Health
A billion people worldwide are obese and Ozempic and other weight-loss drugs aren’t a solution, WHO says
By Naomi Kresge, Angela Feliciano and BloombergMarch 1, 2024
Minnesotans can buy insulin for just $35 a month over the next 5 years under a state settlement with Eli Lilly
Health
Minnesotans can buy insulin for just $35 a month over the next 5 years under a state settlement with Eli Lilly
By Steve Karnowski and The Associated PressFebruary 8, 2024
Novo Nordisk hits $500B market value, climbing closer to the $1T club as it forecasts Wegovy and Ozempic will juice another 29% jump in profits this year
Retail
Novo Nordisk hits $500B market value, climbing closer to the $1T club as it forecasts Wegovy and Ozempic will juice another 29% jump in profits this year
By Ryan HoggJanuary 31, 2024
North Carolina drops coverage for Wegovy and Ozempic, with implications for anti-obesity drug market projected to hit $100B by 2030
Health
North Carolina drops coverage for Wegovy and Ozempic, with implications for anti-obesity drug market projected to hit $100B by 2030
By Simone Foxman, Madison Muller and BloombergJanuary 27, 2024
Alphabet’s Isomorphic Labs to collaborate with Novartis, Lilly on AI-driven drug discovery
Health
Alphabet’s Isomorphic Labs to collaborate with Novartis, Lilly on AI-driven drug discovery
By Susanne Barton and BloombergJanuary 8, 2024
Eli Lilly and Company says its popular drugs Mounjaro and Zepbound, also known as GLP-1s, are not meant for those without obesity or type 2 diabetes.
Health
Eli Lilly cracks down on the use of weight loss drugs Mounjaro and Zepbound for ‘cosmetic’ reasons instead of for diabetes and obesity
By Alexa MikhailJanuary 4, 2024
Career advice from the CFOs of Dell, Eli Lilly, and Marriott—3 women who have each spent 20-plus years climbing the ladder at one company
Newsletters
Career advice from the CFOs of Dell, Eli Lilly, and Marriott—3 women who have each spent 20-plus years climbing the ladder at one company
By Sheryl EstradaDecember 4, 2023
Weight loss drugs are all the rage.
Health
Pfizer rocked by failure of weight-loss pill set to compete with lucrative rivals Ozempic and Mounjaro
By Madison Muller and BloombergDecember 1, 2023
Lars Fruergaard Jorgensen holding a microphone in one hand and paper flashcards in the other hand
Health
Wegovy maker Novo Nordisk could make prices flexible—without cutting them—to persuade more health systems to cover the weight-loss drugs
By Prarthana PrakashNovember 27, 2023
a box of wegovy injectables
Retail
Scientists have discovered a new benefit to Novo Nordisk’s weight-loss drug Wegovy: It can cut heart-related deaths by 20%, drugmaker reports
By Prarthana PrakashNovember 13, 2023
FDA approves yet another weight loss drug to compete against blockbuster sellers Ozempic and Wegovy
Health
FDA approves yet another weight loss drug to compete against blockbuster sellers Ozempic and Wegovy
By Madison Muller and BloombergNovember 8, 2023
picture of four wegovy injections lined up
Health
Novo Nordisk isn’t alone: Sales of Ozempic rival Mounjaro explode as drugmaker Eli Lilly profits from Americans’ weight-loss craze
By Prarthana PrakashNovember 3, 2023
Eli Lilly
Health
New weight-loss blockbuster drug emerges from study showing Mounjaro helps people lose 25% of their body weight or 60 pounds on average
By Jonel Aleccia and The Associated PressOctober 15, 2023
TikTok’s hidden ‘Ozempic economy,’ where weight-loss influencers trade referrals for drug discounts and cash
Tech
TikTok’s hidden ‘Ozempic economy,’ where weight-loss influencers trade referrals for drug discounts and cash
By Alexandra SternlichtSeptember 19, 2023
woman measuring her waist with a tape measure.
Health
Blockbuster weight loss drugs Ozempic and Wegovy cost Americans up to 10 times more than what other countries pay, research shows
By Christiaan HetznerAugust 18, 2023
1
  • 2
  • 3
  • 4
  • 5
  • 6
7
Most Popular
Big Tech
As Big Tech showers employees with perks to win the talent war, Nvidia built a nearly $5 trillion company by making people pay for their own lunchplaceholder alt text
By Marco Quiroz-GutierrezJuly 1, 2026
Success
MacKenzie Scott alone accounted for one-third of America's $19.2 billion in megagifts last yearplaceholder alt text
By Sydney LakeJune 25, 2026
Personal Finance
Current price of oil as of July 1, 2026placeholder alt text
By Joseph HostetlerJuly 1, 2026
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • World's Most Admired Companies
  • See All Rankings
  • Lists Calendar
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.